Understanding and targeting resistance mechanisms in NSCLC

Date: 
25 Oct 2017
Source: 
Nature
Audience: 
Patients and public
Professionals
Type of resource: 
Research

The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances, advanced-stage NSCLC remains largely incurable due to therapeutic resistance. 

 

Click here to read the research article in full